Research programme: interleukin-2 mimetic peptide - AplaGen

Drug Profile

Research programme: interleukin-2 mimetic peptide - AplaGen

Alternative Names: AGIL2-03; Research programme: IL2 mimetic peptide - AplaGen

Latest Information Update: 30 Jan 2007

Price : $50

At a glance

  • Originator AplaGen
  • Class
  • Mechanism of Action Interleukin 2 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 30 Jan 2007 This programme is still in active development for cancer in Germany
  • 30 Nov 2005 Preclinical trials in Cancer in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top